GlassScriptPhysician profile
Michael P Guarisco
NPI 1699830539
$2,795.58
in general payments reported to CMS, 2019-2025
23 companies · $18.36 in 2025
The $18.36 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $743 · 2021: $344 · 2022: $379 · 2023: $529 · 2024: $346 · 2025: $18.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $468.41 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $418.84 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.49 | 2019-2024 | Jardiance |
| Pfizer INC. | $212.27 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.85 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $145.97 | 2019-2022 | |
| Glaxosmithkline, LLC. | $129.54 | 2019-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $125.60 | 2019-2023 | Verquvo, Belsomra |
| Exact Sciences Corporation | $124.33 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $121.53 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.98 | 2023 | |
| Abbott Laboratories | $88.33 | 2023-2024 | Freestyle Libre 3 |
| Eisai INC. | $64.25 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $62.50 | 2022-2023 | Quviviq |
| Gilead Sciences, INC. | $60.38 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $46.73 | 2019-2024 | Airsupra |
| Amgen INC. | $36.28 | 2019-2020 | |
| Horizon Therapeutics Plc | $34.77 | 2023 | Krystexxa |
| Allergan, INC. | $29.80 | 2019-2020 | |
| Lundbeck LLC | $27.85 | 2024 | Rexulti |
| Biocryst US Sales Co., LLC | $18.49 | 2023 | Orladeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.66 | 2023 | Trulance, Xifaxan |
| Abbvie INC. | $12.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Guarisco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.